Pharmacokinetic/pharmacodynamic parameters and the choice of high-dosage rifamycins

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 9, 2012, Pages 1186-1189

  Mitchison, Denis A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Isoniazid; Peak concentrations; Persisters; PKPD; Rifamycins

Indexed keywords

ISONIAZID; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GENE; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN; INHA GENE; KATG GENE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TUBERCULOSIS;

ACETYLATION; ANIMALS; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; HUMANS; ISONIAZID; MICE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; RIFAMYCINS; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84865270067     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0818     Document Type: Article

References (17)

1. Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003; 47: 2118-2124. (Pubitemid 36753560)
2. Jayaram R, Shandil R K, Gaonkar S, et al. Isoniazid pharmaco-kinetics- pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2004; 48: 2951-2957. (Pubitemid 38989160)
3. Mitchison D A. Antimicrobial therapy of tuberculosis: justification for currently recommended treatment regimens. Semin Respir Crit Care Med 2004; 25: 307-315. (Pubitemid 38857283)
4. Dorman S, Goldberg S, Feng P. A phase II study of a rifapentine- containing regimen for intensive phase treatment of pulmonary tuberculosis: preliminary results for Tuberculosis Trials Consortium Study 29. Am J Respir Crit Care Med 183; 2011: A6413.
5. Mitchison D A. Plasma concentrations of isoniazid in the treatment of tuberculosis. In: Davies D S, Pritchard B N C. Biological effects of drugs in relation to their plasma concentration. London, UK: British Pharmacological Society, Macmillan, 1973: pp 169-182.
6. Tuberculosis Chemotherapy Centre, Madras. A concurrent comparison of isoniazid plus PAS with three regimens of isoniazid alone in the domiciliary treatment of pulmonary tuberculosis in South India. Bull World Health Organ 1960; 23: 535-585.
7. Tuberculosis Chemotherapy Centre, Madras. The prevention and treatment of isoniazid toxicity in the therapy of pulmonary tuberculosis. 1. An assessment of two vitamin B preparations and glutamic acid. Bull World Health Organ 1963; 28: 455- 475.
8. Tuberculosis Chemotherapy Centre, Madras. The prevention and treatment of isoniazid toxicity in the therapy of pulmonary tuberculosis. 2. An assessment of the prophylactic effect of pyridoxine in low dosage. Bull World Health Organ 1963; 29: 457-481.
9. Canetti G, Grosset J. Teneur des souches sauvages de Mycobacterium tuberculosis en variants résistants à l'isoniazide et en variants résistants à la streptomycine sur milieu de Löwenstein- Jensen. Ann Inst Pasteur (Paris) 1961; 101: 28- 46. [French]
10. Selkon J B, Devadatta S, Kulkarni K G, Mitchison D A, Nair C N, Ramachandran K. The emergence of isoniazid-resistant cultures in patients with pulmonary tuberculosis during treatment with isoniazid alone or isoniazid plus PAS. Bull World Health Organ 1964; 31: 273-294.
11. Wayne L G, Hayes L G. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of non-replicating persistence. Infect Immun 1996; 64: 2062-2069. (Pubitemid 26165667)
12. Hu Y, Mangan J A, Dhillon J, et al. Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide. J Bacteriol 2000; 182: 6358-6365.
13. Weiner M, Peloquin C, Egelund E, et al. Rifapentine exposure in a trial of daily rifapentine compared to rifampin during the intensive phase of TB treatment. Am J Respir Crit Care Med 2011; 183: A6341.
14. Rosenthal I M, Zhang M, Williams K N. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007; 4: e344.
15. Dhillon J, Lowrie D B, Mitchison D A. Mycobacterium tuberculosis from chronic murine infections that grows in liquid but not on solid medium. BMC Infect Dis 2004; 4: 51.
16. Sirgel F, Fourie B, Donald P, et al. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med 2005; 172: 128-135. (Pubitemid 40923325)
17. Diacon A H, Patentia R F, Venter A, et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother 2007; 51: 2994-2996. (Pubitemid 47206244)